SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administration (FDA) has ...
Dexcom Smart Basal is FDA cleared and now the first and only CGM-integrated basal insulin dosing optimizer for adults aged 18 and older with Type 2 diabetes who are using long-acting insulin. Dexcom ...
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid ...
According to DataM Intelligence, the Insulin Delivery Devices Market Size reached USD 20.26 billion in 2024 and is projected to reach USD 43.11 billion by 2033, growing at a strong CAGR of 8.8% from ...
Nov 6 (Reuters) - Medical device maker Insulet (PODD.O), opens new tab on Thursday posted third-quarter results that surpassed Wall Street's expectations on strong demand for its wearable insulin ...
If low glucose events occur, Dexcom Smart Basal lowers the user’s insulin dose recommendation by the amount set by their ...
Dexcom has been hit by a major safety issue for an Android version of its G6 continuous glucose monitoring system app, leading the FDA to issue its most serious recall notice. A “software defect in ...
New RAMQ coverage means eligible Québec residents with type 2 diabetes on intensive insulin therapy can now access Dexcom Continuous Glucose Monitoring (CGM) to simplify diabetes management. MONTREAL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback